Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 11/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | C1R | P00736 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987661 | 0.93 | ADORA3 (0.40) | MCHR1ADRA2AADORA3NPY5RADORA1 | |
| SCHEMBL22987584 | 0.89 | ADORA3 (0.40) | ADORA3ADORA1C1RCSNK1A1CSNK1D | |
| SCHEMBL22987958 | 0.88 | ADORA3 (0.39) | ADORA3ADORA1C1R | |
| SCHEMBL22979544 | 0.87 | C1R (0.42) | ADORA3ADORA1C1R | |
| SCHEMBL29646400 | 0.87 | C1R (0.42) | ADORA3ADORA1C1R | |
| SCHEMBL22987666 | 0.85 | HSP90AB1 (0.43) | ADORA3 | |
| SCHEMBL22987588 | 0.85 | ADORA3 (0.39) | ADORA3ADORA1CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL22987590 | 0.84 | ADORA3 (0.41) | ADORA3ADORA1C1RCSNK1A1CSNK1D | |
| SCHEMBL22987555 | 0.83 | ADORA3 (0.43) | ADORA3ADORA1CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL22988173 | 0.83 | ADORA3 (0.41) | ADORA3ADORA1C1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | MCHR1 185/4885ADRA2A 207/4885ADORA3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.